Search results for: 'value us'

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing Asia-Pacific (APAC) pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing...

The Malaysia healthcare outlook addresses the investment opportunities across various segments. The study explores the developments in the hospital industry, IVD and POCT industry, pharmaceutical industry, biotechnology industry, medical devices industry, connected health industry, and the aged care industry in the country. The study explores oppor...

This research service provides an analysis for the healthcare market in Vietnam. In addition to an overview of the total healthcare market, it presents detailed analyses of current trends, market sizes, revenue forecasts, and drivers and restraints for the hospital (private and public) market, and for the manufacturing and distribution of medical d...

Indonesia has become one of the most attractive markets for investors during 2014-2015. Implementation of the Jaminan Kesehatan Nasional (JKN) scheme, initiated in January 2014, has been one of the major drivers besides the initiatives by the new government elected in 2014. As per the initial reports, patient volumes have significantly increased af...

06 May 2016  |  Asia Pacific  |  Market Research

Global Generic Pharmaceuticals Market, Forecast to 2020

Market Participants Target High Value-added Branded Generics and Biosimilars Segments

Infographics

×

The key objectives of this research service are to gain an in-depth knowledge of the major markets and therapeutic areas and organizations presenting significant growth opportunities for generics, to understand the impact of regulation on the market, and to outline the industry consolidation trends that will continue shaping the future of generics....

The infectious disease IVD market in Indonesian presents diversified growth potential for different tiers of participants. Domestic participants stand to gain from the growth momentum in the lower-end market, whereas foreign leading manufacturers dominate the higher-end market. This research service analyses the infectious disease IVD market and p...

This study presents an overview of the Asia-Pacific infectious disease point-of-care testing (POCT) market with an emphasis on some of the key trends and growth opportunities that are shaping the market. The study highlights some of the emerging business models supporting the development and adoption of innovative diagnostic tests. The Asia-Pacif...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...